UPB
Upstream Bio, Inc.
NASDAQ · USHealthcareBiotechnology
$6.98-0.43%
Price as of Jul 20, 2026
UPB growth
Upstream Bio, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +44.7%
- EBITDA
- -74.2%
- EBIT
- -81.5%
- EPS
- -70.2%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
- Revenue
- -27.2%
- EBITDA
- +98.5%
- EPS
- -18.2%
Three-year CAGR
- Revenue
- +33.0%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- -78.5%
- Free cash flow
- —
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.